Compare BHB & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHB | RIGL |
|---|---|---|
| Founded | 1887 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.8M | 628.4M |
| IPO Year | 1995 | 2000 |
| Metric | BHB | RIGL |
|---|---|---|
| Price | $32.16 | $26.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $36.67 | ★ $45.67 |
| AVG Volume (30 Days) | 167.4K | ★ 360.8K |
| Earning Date | 04-16-2026 | 03-03-2026 |
| Dividend Yield | ★ 3.99% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | 2.31 | ★ 19.48 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $22.68 | N/A |
| Revenue Next Year | $3.66 | $12.75 |
| P/E Ratio | $13.93 | ★ $1.34 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $26.43 | $15.50 |
| 52 Week High | $36.05 | $52.24 |
| Indicator | BHB | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 33.33 |
| Support Level | $28.38 | $26.38 |
| Resistance Level | $32.60 | $30.59 |
| Average True Range (ATR) | 0.96 | 1.03 |
| MACD | 0.12 | 0.13 |
| Stochastic Oscillator | 87.44 | 36.23 |
Bar Harbor Bankshares Inc is a bank holding company along with its subsidiaries that offers a full range of financial services products, brokerage services through third-party brokerage arrangements and also trust and investment management services to individuals, businesses, non-profit organizations, and municipalities. The company has following reportable segments such as Commercial construction, Commercial real estate owner occupied and non-owner occupied, Tax Exempt, Commercial and industrial loans, Residential real estate, Home equity and Consumer other. Its products and services consist of checking, deposits, cards, mobile banking, online services, loans, merchant services, trust, and fiduciary services, investment planning, education funding, individual retirement planning..
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.